Morgan Stanley Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $165 to $200.
June 24, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Sarepta Therapeutics and raises the price target from $165 to $200.
The increase in the price target from $165 to $200 by a reputable analyst at Morgan Stanley is likely to boost investor confidence in Sarepta Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100